Cancer

IV Drip
First Opinion

Using CRISPR for the ‘smaller wins,’ like making chemotherapy less toxic

By Eric B. Kmiec

Exosomes
In the Lab

Tumor cells can unleash tiny weapons to ward off immune system attacks, study finds

By Megan Thielking

Dr. Steven Rosenberg
In the Lab

After 30 years, an immunotherapy to rival CAR-T finally nears the clinic

By Sharon Begley

Colon Cancer Cell line
In the Lab

Study describing genetic instability in cancer cell lines is a ‘wake-up call’ for scientists, drug developers

By Justin Chen

CAR-T Cell Therapies
Biotech

Regeneron and Bluebird Bio strike a deal to discover and develop cancer treatments

By Ed Silverman

Immunotherapy scans
Politics

To pay for cutting-edge CAR-T therapies, Medicare plays it safe, for now

By Ike Swetlitz

The Readout LOUD

LISTEN: Biotech’s sellers market, Sanofi’s second act, and literally climbing Mt. Everest

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Exclusive

In shift, IBM is adding regional treatment advice and real patient data to cancer product

By Ike Swetlitz and Casey Ross

Gene Therapy Recruiters
Biotech

Stock, sky-high salaries and a $10,000 watch: Startups desperately compete for top experts in gene and cell therapy

By Rebecca Robbins

A photo of Venture capitalist Lisa Suennen.
Business

VCs are pouring money into digital health. Are they making smart bets?

By Rebecca Robbins and Adam Feuerstein

Thyroid Surgery
First Opinion

De-intensifying treatment for early thyroid cancer

By H. Gilbert Welch and Gerard M. Doherty

Sick Watson
Exclusive

IBM’s Watson supercomputer recommended ‘unsafe and incorrect’ cancer treatments, internal documents show

By Casey Ross and Ike Swetlitz

In the Lab

A CAR-T bottleneck: Centers that collect patient cells feel crunch from growing demand

By Andrew Joseph

Seema Verma CAR-T
Politics

U.S. ended value-based pricing plan for cancer drug because of doubts it would work

By Ike Swetlitz

Elijah Cummings 2017
Pharmalot

Cummings probes Trump administration official over potential conflicts with drug maker

By Ed Silverman

Engineered Cancer Cells
In the Lab

CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds

By Sharon Begley

Health

Physicians’ beliefs may override cancer patients’ wishes for end-of-life care, study finds

By Orly Nadell Farber

Human T lymphocyte
Biotech

Seeking to unleash immunotherapies on solid tumors, biotech homes in on cell receptors

By Andrew Joseph

First Opinion

Opioid stigma is keeping many cancer patients from getting the pain control they need

By Sara Ray and Kathleen Hoffman

Health

New approach to breast cancer screening — tailoring guidelines for each patient — may save lives and money, study says

By Orly Nadell Farber

TGF Beta
Biotech

Biopharma has a new big idea for making cancer immunotherapy work better

By Damian Garde

Cancer Evolution Crab
First Opinion

Using the principles of evolution to treat and prevent cancer

By James DeGregori

Health

Poliovirus therapy shows early promise in patients with aggressive brain cancer but questions linger

By Adam Feuerstein

China Pharmacy
Business

How are drug makers going to make money in China? An explainer

By Rebecca Robbins

Elderly Immunotherapy
First Opinion

We need more answers about immunotherapy for the elderly

By Ankur Parikh

Pancreatic cancer cells
Health

Muscle and fat loss may offer clues to pancreatic cancer’s deadly ways

By Justin Chen

Wong Maye-E/AP
First Opinion

Barriers to genomic testing get in the way of precision medicine

By Chadi Nabhan

First Opinion

New Gardasil ad campaign gets it (mostly) right. It shouldn’t have taken a decade

By Ashley Andreou

Biotech

China just approved its first cancer immunotherapy drug. Here’s what’s next in the pipeline

By Rebecca Robbins

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy